We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · October 22, 2020

Final Analysis of Ipilimumab vs Placebo Following Radiotherapy in Postdocetaxel mCRPC Identifies an Excess of Long-Term Survivors

European Urology


Additional Info

European Urology
Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-Resistant Prostate Cancer Identifies an Excess of Long-Term Survivors
Eur Urol 2020 Aug 15;[EPub Ahead of Print], K Fizazi, CG Drake, TM Beer, ED Kwon, HI Scher, WR Gerritsen, A Bossi, AJMV den Eertwegh, M Krainer, N Houede, R Santos, H Mahammedi, S Ng, R Danielli, FA Franke, S Sundar, N Agarwal, AM Bergman, TE Ciuleanu, E Korbenfeld, L Sengeløv, S Hansen, MB McHenry, A Chen, C Logothetis

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading